Side-by-Side Comparator
Compare two therapeutic candidates head-to-head across multi-source evidence dimensions: PubMed literature citation volume, ClinicalTrials.gov termination signals, openFDA adverse event reports, Open Targets genetic validation, and evidence-graded failure modes.
Benchmark Presets:
Side-by-Side DiligenceMulti-Source Evidence Differential
Candidate Comparison
ACandidate A
Composite Score: 86/100osimertinib × non-small cell lung cancer (EGFR)
Compound: osimertinibTarget: EGFRIndication: non-small cell lung cancerModality: small molecule🏷️ High Priority🏷️ Watchlist🏷️ Internal
Sources: 7 verified
BCandidate B
Composite Score: 76/100gefitinib × non-small cell lung cancer (EGFR)
Compound: gefitinibTarget: EGFRIndication: non-small cell lung cancerModality: small molecule🏷️ Historical🏷️ Watchlist
Sources: 6 verified
Overall Score Differential:▲ Candidate A leads by +10 pts
PubMed Hits: 8430 vs 14200CT.gov Trials: 184 vs 245Early Stops: 14 vs 38
1. Transparency & Evidence Scores Differential
Side-by-side dimension scores (0–100) grounded in open-access registries.
| Dimension | Cand. A (osimertinib) | Cand. B (gefitinib) | Differential (Δ) | Evidence Grounding & Rationale |
|---|---|---|---|---|
| Literature Evidence | 92/100 | 96/100 | -4 (B lead) | A: Extensive peer-reviewed clinical and mechanistic literature (>8,400 PubMed hits) B: Historical foundation with massive literature base (>14,000 PubMed citations) |
| Clinical Trial Precedent | 88/100 | 74/100 | +14 (A lead) | A: Large Phase 3 registrational dataset (FLAURA, ADAURA) with strong CNS penetration signal B: Pivotal trials (IPASS) established biomarker paradigm, but limited by 50% T790M attrition at 10-12 months |
| Target Validation | 95/100 | 92/100 | +3 (A lead) | A: EGFR driver mutation genetically verified with robust Open Targets association (0.94/1.0) B: Direct reversible ATP-competitive inhibition of wild-type and L858R EGFR |
| Safety & Tolerability | 68/100 | 54/100 | +14 (A lead) | A: Well-tolerated relative to 1st/2nd gen TKIs; FAERS signals note QT prolongation and pneumonitis risk B: High wild-type EGFR inhibition triggers severe acneiform rash (65%) and diarrhea; FAERS hepatotoxicity signals |
| Translational Feasibility | 85/100 | 62/100 | +23 (A lead) | A: Irreversible covalent binding to C790 spares wild-type EGFR; overcomes T790M resistance B: Lacks covalent binding; cannot overcome steric hindrance of T790M gatekeeper mutation; poor CNS penetration |
Comparing osimertinib × non-small cell lung cancer (EGFR) vs gefitinib × non-small cell lung cancer (EGFR)